Health Care Technology

This is your Benzinga news summary and traders' outlook for Wednesday, August 3, 2011, covering headlines from overnight and Wednesday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are set to rebound today after moving into negative territory for the year...

FBR Capital upgraded AeroVironment Inc (NASDAQ: AVAV) from “market perform” to “outperform.” AVAV's shares closed at $28.10 yesterday. AeroVironment's PEG ratio is 1.07. Robert W. Baird upgraded Fiserv Inc (NASDAQ: FISV) from “neutral” to “outperform.” Fiserv's shares closed at $57.88 yesterday....

Goldman Sachs reiterated its Neutral rating on Allscripts Healthcare Solutions (NASDAQ: MDRX). At the same time, the rating agency left its price target on the company's stock unchanged at $21. On Tuesday, MDRX lost 7.05% of its value to end the day at $16.74. Its shares rebounded in today's pre-...

SXC Health Solutions Corp. (NASDAQ: SXCI) announced today that it has entered into a definitive agreement to acquire PTRx, Inc., a full-service PBM, and SaveDirectRx, its exclusive mail-order pharmacy provider, both based in San Antonio. The purchase price of $77 million in cash is to be paid from...

Morgan Keegan has lowered the price target on Allscripts (NASDAQ: MDRX) from $27 to $24 and maintains its Outperform rating.

Piper Jaffray has upgraded Allscripts (NASDAQ: MDRX) from Neutral to Overweight and has established a $22 price target.

According to Morgan Keegan, MedAssets (NASDAQ: MDAS) saw a strong quarter. Morgan Keegan said that MDAS reported June results of $0.23 on $147.9 million versus consensus of $0.16 on $145.5 million. “We believe the cash flow enhancing software/services that MDAS provides will be in high demand as...

Auriga is out with its report today on MedAssets (NASDAQ: MDAS), reiterating Buy. In its report, Auriga writes, "In our view, MDAS' narrowed EPS range of $0.96-$1.02 on albeit a slightly weaker revenue guide is impressive enough to offset the tremendous negative sentiment heading into earnings. We...

Morgan Keegan has lowered the price target on MedAssets (NASDAQ: MDAS) from $24 to $22 and maintains its Outperform rating.

Oppenheimer has published a report on MedAssets Inc (NASDAQ: MDAS) reviewing the second quarter and lowering the PT from $21 to $20. In the report, Oppenheimer wrote, "MedAssets reported better than expected results, primarily on the early recognitionof RCM incentive fees. As has been widely...

J.P. Morgan is out with its report today on MedAssets (NASDAQ: MDAS), maintaining Neutral. In its report, J.P. Morgan writes, "We maintain our Neutral recommendation given a lackluster outlook for the balance of 2011, but note that with the stock trading at just 11.3x our 2012E EPS, there appears...

Piper Jaffray reiterated its Underweight rating on MedAssets (NASDAQ: MDAS). At the same time, the rating agency reduced its price target on the company's stock from $11 to $10. On Monday, MDAS lost 5.29% of its value to finish the day at $12.

Piper Jaffray has lowered the price target on MedAssets (NASDAQ: MDAS) from $11 to $10 and maintains its Underweight rating.

Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...

Transcend (NASDAQ: TRCR) today announced its acquisition of Salar Inc. in an $11 million cash for stock transaction that closed July 29, 2011. It is anticipated that the acquisition will give Transcend a stronger foothold in the hospital setting and provide its customers added functionality and...